



Press release |  
Regulated information

**IBA COMPLETES PROTON SYSTEM AND FIRST TREATMENT ROOM  
IN RECORD TIME  
AT PROCURE'S NEW JERSEY CENTER**

**Somerset, New Jersey, March 20, 2012** — IBA, the Belgium based manufacturer of cancer-fighting Proton Therapy systems, continues to accelerate the pace at which newly constructed Proton Therapy centers are ready to treat patients.

Last month, **less than one year** after the arrival of its Proteus 235 cyclotron at the 60,000-square-foot Somerset facility, IBA completed installation of the cyclotron, beam line and the first of four state-of-the-art treatment rooms. IBA engineers and medical physicists hit their previous installation record set at CDH Proton Center, a ProCure Center, in Warrenville, Illinois, a Chicago suburb.

Clinicians at the ProCure Proton Therapy Center in Somerset, New Jersey, will treat the first patients the week of March 26. At full capacity, the center will treat about 1,500 patients per year.

“With this unrivalled achievement, IBA underscores our competitive edge in delivering operational proton systems to cancer clinics and academic health centers,” said Olivier Legrain, Chief Operating Officer at IBA. **“Such assurance helps medical institutions reduce their technological and financial risk.”**

“They say, ‘Practice makes perfect,’” Olivier Legrain said. “And with each new proton system installation, IBA continues to improve timelines, helping to ensure cancer centers open sooner and begin treating patients with protons more quickly.” Olivier Legrain will succeed Pierre Mottet as IBA’s Chief Executive Officer in May.

Of the nine Proton Therapy centers currently operating in the United States, seven are IBA installations, including ProCure facilities in Oklahoma City, Oklahoma, and Warrenville, Illinois.

IBA is committed to making Proton Therapy, the most accurate cancer treatment, available worldwide. IBA is the only supplier to have multiple centers treating cancer patients with Pencil Beam Scanning (PBS), the most precise form of Proton Therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.



## Press release |

Regulated information

Proton Therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. As documented in recent studies of children receiving Proton Therapy, higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

### **ABOUT IBA**

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for health care with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

*IBA is listed on the pan-European stock exchange EURONEXT.*

*(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).*

Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### Contact

#### **IBA**

#### **Bill Hansen**

Director of Marketing

Phone : +1 612-804-5559

E-mail: [William.Hansen@iba-group.com](mailto:William.Hansen@iba-group.com)

#### **Sandrine Leriche**

VP Corporate Communication

Phone : +32 10 47 58 90

E-mail : [Sandrine.Leriche@iba-group.com](mailto:Sandrine.Leriche@iba-group.com)